01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Pancreatic exocrine insufficiency means that pancreatic digestive activity in the intestine is inadequate for normal digestion, causing clinically relevant maldigestion. Chronic pancreatitis, severe acute pancreatic injury, pancreatic surgery and obstructing disease are important contexts, but the diagnosis is not made from an imaging label alone. Fat maldigestion is often conspicuous, yet the clinical consequences extend to energy and nutrient deficits, reduced muscle function and poorer quality of life.
An enzyme prescription works only if an appropriate amount reaches the gut with food. A patient can collect every prescription and still receive little benefit because the capsules are taken at the wrong time, the dose is too low for meals, or symptoms have an additional cause. Teaching therefore needs to cover the exact formulation, meal and snack doses, administration and a measurable review plan. It should also explain when the diagnosis needs reconsideration and when pancreatic recovery makes reassessment of continuing replacement appropriate.
Key points
- Exocrine insufficiency is a clinical maldigestion syndrome: combine symptoms, nutritional assessment and pancreatic function testing where appropriate.
- Faecal elastase below 200 micrograms/g is commonly used to support the diagnosis, but no single threshold settles every case; below 100 provides stronger support in a compatible setting.
- Use a formed stool for elastase testing; watery diarrhoea can dilute the sample and give a falsely low result.
- UK guidance starts adults at at least 50,000 lipase units per meal and 25,000 per snack, with enzymes spread through eating.
- Creon 25,000 contains 25,000 lipase units per capsule: start two per main meal and one per snack, then titrate to the food and response.
- Do not crush or chew enzyme granules; if capsules are opened, take intact granules immediately with a suitable acidic vehicle.
- Check timing, access, storage and alternative causes before repeated dose escalation; judge success by nutritional recovery as well as stool symptoms.
- After acute pancreatitis, reassess pancreatic function and continuing need for treatment because exocrine impairment may recover.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Loss or obstruction of pancreatic function
Chronic inflammation, severe acute injury, pancreatic resection and duct obstruction can reduce enzyme delivery. The clinical likelihood and the possibility of recovery depend on the underlying disorder rather than the faecal test result alone.
Digestion and delivery failure
Effective digestion depends on sufficient enzyme activity reaching food in the intestine. Altered anatomy, impaired stimulation or poor mixing can contribute to insufficiency, while incorrect use of replacement can mimic treatment-resistant pancreatic failure.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Inadequate nutrient breakdown
Reduced pancreatic enzyme activity limits digestion of nutrients before absorption. Fat maldigestion is particularly apparent clinically, but nutritional consequences reflect the overall balance between digestive capacity, food intake and the body’s requirements.
- 2Deficits beyond stool symptoms
Energy loss, dietary avoidance and impaired nutrient availability can lead to weight and muscle loss and vitamin deficiencies. These consequences may develop without striking diarrhoea, explaining the need for nutritional assessment alongside symptom review.
- 3Enteric-coated replacement
Creon contains small enteric-coated particles that mix with gastric contents and release enzymes in the small intestine. Damaging the coating or separating the dose from food disrupts this delivery process and may irritate the mouth or reduce effectiveness.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Ask about stool oiliness, difficulty flushing, diarrhoea, bloating and post-meal discomfort, alongside weight, food intake and strength. Some patients reduce fat or skip meals to avoid symptoms, masking steatorrhoea while increasing malnutrition. Absence of obvious oily stool does not establish adequate digestion, particularly when intake has already become restricted.
Establish the pancreatic history and whether a cause has been adequately investigated. Severe necrotizing pancreatitis and established advanced chronic disease create a different pre-test probability from isolated loose stool with no pancreatic history. New unexplained insufficiency requires an assessment for underlying pancreatic disease, including malignancy when suggested, rather than a lifetime repeat prescription without explanation.
A low faecal elastase result supports insufficiency most convincingly when symptoms, nutrition and pancreatic disease agree. A diluted watery specimen can be misleading. Conversely, a non-low value may not end the assessment when the clinical likelihood is high. Use the combined evidence and repeat or seek specialist testing if the result and presentation conflict.
Ask the patient to describe a real meal and exactly when each capsule is taken. Include snacks, milky drinks and oral nutritional supplements, which may also need enzymes. Check swallowing difficulties, access to the prescribed strength and whether the granules have been crushed. Correct these practical problems explicitly rather than documenting adherence as a yes-or-no answer.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Faecal elastase-1 on a formed sampleFirst step - Why
- Obtain a practical indirect measure of pancreatic exocrine function.
- Interpretation and limitations
- A result below 200 micrograms/g is a commonly used supportive threshold and below 100 is more strongly suggestive, but the current European guideline does not endorse an absolute cutoff that diagnoses every patient. Repeat a low result obtained from watery stool on a formed sample, or follow laboratory adjustment advice. Human elastase testing is not invalidated by taking porcine enzyme replacement.
- 02
Nutritional assessment and blood tests - Why
- Identify the consequences of maldigestion and establish outcomes for follow-up.
- Interpretation and limitations
- Record serial weight, dietary intake, muscle function and relevant micronutrients, including fat-soluble vitamins where indicated. Interpret results in the clinical context: one normal marker or a normal BMI does not exclude malnutrition. Dietetic assessment helps distinguish inadequate consumption from impaired digestion and guides replacement of identified deficiencies.
- 03
Pancreatic imaging and cause review - Why
- Identify structural pancreatic disease or an obstructing lesion.
- Interpretation and limitations
- CT, MRI and EUS assess the cause and complications; they do not directly measure adequate digestion. New insufficiency without an established explanation needs an appropriate pancreatic assessment. A visible structural abnormality can strengthen clinical suspicion, but diagnosis and treatment still require attention to nutritional and functional consequences.
- 04
Assessment of persistent symptoms - Why
- Find an incorrect regimen or an additional gastrointestinal disorder.
- Interpretation and limitations
- First review dose, timing, storage, access and whether all relevant food is covered. If symptoms persist despite a correctly taken adequate dose, consider small-bowel bacterial overgrowth, coeliac disease, bile-acid diarrhoea, inflammatory or microscopic colitis, infection, medication effects and constipation with overflow according to the history. Escalating enzymes cannot treat these alternative mechanisms.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Dilution of faecal elastase
Watery stool can lower the measured elastase concentration even without true pancreatic insufficiency. A repeat formed sample and clinical correlation help prevent a misleading result from becoming an unsupported permanent diagnosis.
Non-pancreatic diarrhoea
Coeliac disease, bile-acid diarrhoea, bacterial overgrowth, intestinal inflammation and infection can cause overlapping symptoms. They may coexist with genuine pancreatic insufficiency and need assessment when a correctly used replacement regimen remains ineffective.
Inadequate intake or medication effects
Dietary restriction, laxatives, other medicines and constipation with overflow can resemble or worsen maldigestion symptoms. A detailed history can reveal these contributors without assuming that all persistent loose stools require additional enzymes.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Worked caseMaking an existing prescription effectiveFirst stepA 46-year-old woman recovering from severe acute pancreatitis has a formed-stool elastase of 64 micrograms/g and persistent greasy stools despite Creon 25,000, one capsule with each meal.+
- 1A meal review shows that she takes the capsule with a drink well before food and has no enzymes with snacks. The team changes the regimen to two 25,000-unit capsules per main meal, spread through eating, and one with a snack. She receives practical instructions for intact granules, adequate hydration and the current product cautions, and a dietitian reviews food intake without imposing routine fat restriction.
- 2AlternativeAt the two-week review, stool oiliness has improved but her largest evening meal still produces symptoms. Administration is now correct and no alternative cause is apparent, so the team gradually increases that meal to three capsules, retaining two with smaller meals and one with snacks. Three weeks later her stool frequency has fallen from four to two daily and her weight has increased by 1 kg.
- 3Because the insufficiency followed acute pancreatitis, the team schedules reassessment of symptoms, nutrition and pancreatic function at approximately three, six and twelve months after discharge. Continuing treatment is adjusted to demonstrated need; an early clinical response does not prove permanent loss of function, and later withdrawal is a supervised decision after reassessment.
02Start with a complete prescriptionClinically important maldigestion is established or strongly suspectedA patient’s pancreatic history, symptoms and nutritional findings support exocrine insufficiency.+
- 1Investigate an unexplained cause and obtain appropriate baseline nutrition and function tests, but do not delay necessary nutritional treatment in a high-likelihood patient while waiting for every result. Explain that the replacement is derived from porcine pancreatin and discuss any concern about its origin, formulation or use with food.
- 2Prescribe a named strength in lipase units and translate it into capsules for the patient. A UK adult starting regimen is at least 50,000 units with each meal and 25,000 with a snack; for Creon 25,000 this is two and one respectively. Spread the dose during eating and explain coverage of nutritional supplements and substantial milky drinks.
- 3Arrange a defined early review of symptoms, intake, weight and use of the medicine. Increase gradually where the response remains inadequate after correcting administration, often in stepwise increments according to meal size and fat content. Treat identified nutrient deficiencies and use dietetic support to restore adequate food rather than routinely restricting dietary fat.
03Troubleshoot and reassessA patient remains symptomatic or requires large dosesInitial enzyme replacement has not produced an adequate clinical and nutritional response.+
- 1Confirm the actual capsule strength, the number taken, meal and snack timing and storage conditions. Enzymes taken without the relevant food, granules damaged by chewing or a missed supply are correctable causes of failure. Do not assume that changing brands without checking equivalent lipase units will solve the problem.
- 2EscalationReview other causes of symptoms when more than 100,000 lipase units per meal are needed; if symptoms continue at 10,000 units/kg/day, investigate before further escalation. These are review triggers, not proof of a universal adult maximum dose. A specialist may consider acid suppression after correct dosing and timing have been established, weighing its separate indication and adverse effects.
- 3Reassess the underlying disease and the need for continued replacement. Post-acute-pancreatitis function may improve, whereas established chronic disease commonly needs sustained treatment and monitoring. Continue six-to-twelve-month reassessment if post-acute insufficiency persists, and provide a clear plan for responding to new symptoms, nutritional decline or product intolerance.
Key medicines and prescribing safety1 treatment · regimens, roles and cautions+
Creon 25,000: 25,000 lipase units per capsule
Adult starting example: two capsules (50,000 lipase units) during each main meal and one (25,000 units) with each snack; distribute capsules through the meal. Titrate gradually to food content and clinical/nutritional response. If swallowing is difficult, open the capsule onto acidic soft food or fluid with pH <5.5, swallow the intact granules immediately and do not retain the mixture. Keep granules uncrushed and unchewed. Review additional causes above 100,000 units per meal or before further escalation when symptoms persist at 10,000 units/kg/day.Contraindicated in hypersensitivity to porcine pancreatin or an excipient; stop treatment and seek urgent assessment for an allergic reaction. Maintain fluid intake and clear residual granules from the mouth. Investigate unusual abdominal symptoms, particularly during high-dose treatment; the fibrosing-colonopathy warning comes principally from cystic-fibrosis patients above 10,000 lipase units/kg/day. Use caution in renal impairment, gout or hyperuricaemia; the product gives no standard renal/hepatic adjustment table. With extreme overdose and raised urate, stop enzymes and rehydrate. Prescribe cautiously during pregnancy; breastfeeding use is permitted at doses maintaining adequate nutrition. Possible HEV contamination of porcine extracts cannot be excluded: immunosuppressed patients on high daily doses should seek care for viral-hepatitis symptoms. Record the product and batch number. Interaction studies have not been undertaken. Keep tightly closed below 25°C and discard after six months from opening.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Malnutrition and loss of function
Persistent digestive failure can reduce energy reserves, muscle strength and physical capacity. Correction of stool symptoms is therefore only one part of treatment success; recovery of intake and nutritional status also needs demonstration.
Micronutrient and bone effects
Deficiencies, including fat-soluble vitamins, may contribute to longer-term morbidity. In chronic pancreatic disease, exocrine monitoring forms part of a wider programme that also assesses skeletal health and endocrine function.
Treatment-related problems
Hypersensitivity and formulation errors can complicate therapy, while high-dose treatment has specific safety cautions. Unusual abdominal symptoms, very high requirements and immunosuppression call for a careful product-specific review rather than automatic continuation.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- At the initial follow-up, review stool pattern and abdominal symptoms with a concrete account of doses taken across a normal day. Improvement after correcting meal timing is useful evidence that delivery mattered, but it does not independently establish the cause of the pancreatic disorder.
- Follow weight, food intake, muscle function and relevant nutritional blood results. Persistent deficiencies or declining strength require reassessment even when stool frequency is acceptable. Work with a dietitian to adjust the diet and treatment to the patient’s actual needs.
- After acute pancreatitis, the current European guideline suggests reassessing exocrine status around three, six and twelve months after discharge, then every six to twelve months if insufficiency continues. Use symptoms, nutrition and appropriate function testing to guide continuing replacement.
- For chronic pancreatitis, maintain the wider endocrine and bone monitoring programme as well as exocrine review. Ask about adverse effects, unusual abdominal symptoms and supply problems; a switch caused by availability needs a fresh check of lipase-unit equivalence and administration instructions.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
A low test is not the whole diagnosis
Test performance changes with the prior likelihood of disease. The same low elastase result in a watery sample from a patient without pancreatic risk is less persuasive than a low formed-sample result with calcific disease and nutritional decline. Investigate discordance rather than treating the laboratory number in isolation.
Enzymes should meet the food
Enteric-coated granules are designed to travel with the meal and release enzymes in the intestine. Taking the full dose remote from food reduces that intended mixing. A short practical conversation about breakfast, snacks and supplements can be more useful than adding capsules without addressing their timing.
Review thresholds are not unlimited-dose permission
There is no universally established maximum dose for every adult without cystic fibrosis, but this does not justify open-ended escalation. High requirements should prompt review of administration, nutrition, additional disease and adverse effects. Keep the cystic-fibrosis colonopathy evidence distinct from a general adult treatment rule.
Recovery and replacement can coexist
Replacement supports digestion while the underlying pancreas is recovering; it does not itself determine whether the deficit is permanent. A patient recovering from acute pancreatitis may need a later supervised reduction or withdrawal, while someone with persistent disease needs continued access and follow-up. Plan the reassessment when treatment starts.
11Common pitfallsFrequent interpretation and management errors.
- 01
Calling a single low elastase result from a watery specimen definitive evidence of pancreatic insufficiency.
- 02
Giving instructions in milligrams or capsule count without specifying the product’s lipase activity and the intended meal or snack dose.
- 03
Taking all capsules away from food, missing snacks or crushing granules to make them easier to swallow.
- 04
Restricting dietary fat reflexively and overlooking inadequate intake or muscle loss in a patient whose BMI remains normal.
- 05
Increasing the enzyme dose repeatedly without investigating persistent symptoms or reviewing the continuing need after acute pancreatitis.